Skip to main content

Beneficial ownership — 13D / 13G

87,339 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.

Reporting person Issuer Schedule % of class Filed
Tony L. Alford LCU Lion Copper Corp. 13D/A 32.9% 2y
Dunde Yu TOUR Tuniu Corp 13D/A 8.3% 2y
Fang Zheng ZOOZ ZOOZ Strategy Ltd. 13D 21.67% 2y
JANUS HENDERSON GROUP PLC ORKA Oruka Therapeutics, Inc. 13G 7.4% 2y
Millennium Management LLC CMPS COMPASS Pathways plc 13G 5.7% 2y
WOLVERINE ASSET MANAGEMENT LLC DSAQ Direct Selling Acquisition Corp. 13G/A 2.91% 2y
RA CAPITAL MANAGEMENT, L.P. CRVO CervoMed Inc. 13G 9.99% 2y
Dominion Capital LLC HUBC Hub Cyber Security Ltd. 13D/A 0.4% 2y
Granahan Investment Management, LLC INDI indie Semiconductor, Inc. 13G/A 11.78% 2y
WOLVERINE ASSET MANAGEMENT LLC ZPTA Zapata Quantum, Inc. 13G/A 0% 2y
James Michael McCrory IBAC IB Acquisition Corp. 13D 6.6% 2y
ADAGE CAPITAL PARTNERS GP, L.L.C. BNTC Benitec Biopharma Inc. 13G/A 9.99% 2y
F9 Investments, LLC (Single Member LLC with Thomas D. Sullivan Single Member) LL LL Flooring Holdings, Inc. 13D/A 8.8% 2y
LONGVIEW ASSET MANAGEMENT, LLC GD General Dynamics Corp 13D/A 10.3% 2y
TAKEDA PHARMACEUTICAL CO LTD PHAT Phathom Pharmaceuticals, Inc. 13D/A 4.8% 2y
JOHNSON & JOHNSON CTNM Contineum Therapeutics, Inc. 13G 10.7% 2y
Insight Venture Partners X, L.P. S SentinelOne, Inc. 13D/A 8.2% 2y
GAMCO INVESTORS, INC. ET AL KAMN Kaman Corp 13D/A 8.11% 2y
Cloud Alliance Inc QH QUHUO Ltd 13D/A 25.96% 2y
Murat Kalayoglu RNAC Cartesian Therapeutics, Inc. 13D/A 19.9% 2y
Weinzierl John A BSIN Big Sky Industrial Inc. 13D/A 31% 2y
New Enterprise Associates 15, L.P. NEUE NeueHealth, Inc. 13D/A 56.6% 2y
Michael Singer RNAC Cartesian Therapeutics, Inc. 13D/A 4.3% 2y
FAIRFAX FINANCIAL HOLDINGS LTD/ CAN CCAP Crescent Capital BDC, Inc. 13G/A 4.9% 2y
Bluescape Riley Exploration Holdings LLC REPX Riley Exploration Permian, Inc. 13D/A 21.11% 2y
Riley Exploration Group, LLC REPX Riley Exploration Permian, Inc. 13D/A 12.35% 2y
Saba Capital Management, L.P. PEO Adams Natural Resources Fund, Inc. 13D/A 8.23% 2y
Mitsui & Co., Ltd. ATLX Atlas Lithium Corp 13D 12.8% 2y
Peter A. Appel MOVE Corvex, Inc. 13G 9.99% 2y
Y.D. More Investments Ltd ZOOZ ZOOZ Strategy Ltd. 13G 11.81% 2y
Kit Yee Sze NIVF NewGenIvf Group Ltd 13G 5.4% 2y
Kenneth R. Lehman BRBS Blue Ridge Bankshares, Inc. 13D 5.2% 2y
Wing Fung Alfred Siu NIVF NewGenIvf Group Ltd 13D 40.5% 2y
Castle Creek Capital Partners VIII, LP BRBS Blue Ridge Bankshares, Inc. 13D 2.6% 2y
Bank of New York Mellon Corp AFK VanEck ETF Trust 13G/A 11.85% 2y
1607 Capital Partners, LLC MGF Aberdeen Government Markets Income Fund 13G/A 7.57% 2y
PRICE T ROWE ASSOCIATES INC /MD/ GLUE Monte Rosa Therapeutics, Inc. 13G/A 10.2% 2y
JONATHAN KOLBER REAX Real REMAX Group Inc. 13G 6.07% 2y
PRICE T ROWE ASSOCIATES INC /MD/ BPMC Blueprint Medicines Corporation 13G/A 10.2% 2y
Bank of New York Mellon Corp NCLO NuShares ETF Trust 13G/A 10.22% 2y
STATE STREET CORP REPL Replimune Group, Inc. 13G/A 10.57% 2y
GLAZER CAPITAL, LLC AITR AI TRANSPORTATION ACQUISITION CORP Ordinary shares 13G/A 7.21% 2y
Wealthspring Capital LLC KDK Kodiak AI, Inc. 13G/A 10.2% 2y
CITIGROUP INC BVN Buenaventura Mining Co Inc 13G/A 0.2% 2y
STATE STREET CORP EDIT Editas Medicine, Inc. 13G/A 10.71% 2y
RIVERNORTH CAPITAL MANAGEMENT, LLC BRAC Broad Capital Acquisition Corp Common Stock 13G 10.63% 2y
PRICE T ROWE ASSOCIATES INC /MD/ REPL Replimune Group, Inc. 13G/A 10.7% 2y
PRICE T ROWE ASSOCIATES INC /MD/ SMHI SEACOR Marine Holdings Inc. 13G/A 4.7% 2y
STATE STREET CORP CCCC C4 Therapeutics, Inc. 13G 10.43% 2y
EARNEST PARTNERS LLC FCFS FirstCash Holdings, Inc. 13G/A 5.1% 2y